AbbVie ABBV announced that a phase III study — VIALE-C — evaluating a combination regimen of its blood cancer drug, Venclexta (venetoclax), failed to meet primary endpoint. The study evaluated ...

This is not the first clinical setback for Venclexta. In 2023, AbbVie reported that a late-stage study evaluating Venclexta plus dexamethasone in certain multiple myeloma patients also failed to ...

AbbVie edges ahead of Bristol Myers with strong Skyrizi and Rinvoq growth, offsetting Humira declines and portfolio headwinds.

AbbVie, Inc.ABBV announced that the FDA has placed a partial clinical hold on all studies evaluating its leukemia drug, Venclexta (venetoclax) for the treatment of multiple myeloma.

Large-cap biopharmaceuticals AbbVie (ABBV 1.30%) and Roche (RHHBY 0.24%) announced last week that the U.S. Food and Drug Administration (FDA) had granted their joint effort, Venclexta, a ...

Shares of AbbVie were down less than 1 percent following the news. Venclexta, a BCL-2 inhibitor that AbbVie markets with Roche’s Genentech division, was approved in 2016 for second-line chronic ...

Venclexta trial deaths force AbbVie, Roche to stop recruiting myeloma patients The treatment achieved blockbuster status in 2020 and generated sales of $2.6 billion last year, an increase of 13% ...

AbbVie and Roche’s Venclexta has hit the mark in a combination trial that could help it move into the treatment-naive chronic lymphocytic leukaemia (CLL) arena.Top-line results from the CLL14 ...

AbbVie Inc. made a big splash entering the blood cancer treatment market with its $21 billion deal to buy Pharmacyclics last year. The move single-handedly landed AbbVie one of the fastest growing ...